The goal of this clinical trial is to compare two different presentations (vial and syringe versus autoinjector) of navenibart in healthy adult volunteers. The main questions it aims to answer are:
* Do these presentations lead to similar drug concentrations in the blood?
* Do these presentations lead to similar safety and tolerability?
Researchers will compare the drug concentrations and safety profile of each group to determine if they are similar.
Participants will:
* Receive one dose of navenibart with either the vial and syringe or the autoinjector.
* Stay in the clinic beginning one day prior to dosing through 2 days after dosing.
* Return to the clinic for approximately 9 additional non-residential visits.
* Complete medical and other testing, including blood draws.